Fast effectiveness of a solubilized low‐dose budesonide nasal spray in allergic rhinitis. Issue 9 (7th July 2020)

• Record Type: Journal Article
• Authors: Zieglmayer, Petra; Schmutz, René; Lemell, Patrick; Unger‐Manhart, Nicole; Nakowitsch, Sabine; Goessl, Andreas; Savli, Markus; Zieglmayer, René; Prieschl‐Grassauer, Eva
• Is Part Of: Clinical & experimental allergy. Volume 50:Issue 9(2020)
• Page Start: 1065
• Page End: 1077
• Publication Date: 2020-07-07
• Subjects: allergic rhinitis -- budesonide -- challenge chamber -- early onset -- inflammation -- intranasal glucocorticoids -- nasal spray -- preservative‐free; Allergy -- Periodicals; Immunology -- Periodicals; 616.97
• DOI: 10.1111/cea.13691
• Languages: English
• ISSNs: 0954-7894

Abstract

Abstract: Background: Budesonide, a poorly water‐soluble corticosteroid, is currently marketed as a suspension. Budesolv is a novel aqueous formulation containing dissolved budesonide showing increased local availability in preclinical models. Budesolv contains ~85% less corticosteroid than the marketed comparator. Objective: The study (EudraCT:2018‐001324‐19) was designed to assess non‐inferiority of Budesolv compared to Rhinocort® Aqua 64 (RA) and early onset of action. Methods: In a three‐way cross‐over double‐blinded randomized trial, Budesolv 10 was compared to RA and placebo in grass pollen allergic rhinoconjunctivitis volunteers (n = 83 (ITT); n = 75 (PP)). On day 1, participants entered the Vienna Challenge Chamber (VCC) for 6 hours; first treatment took place at 1:45 hours after entry. Participants treated themselves for further 6 days; on day 8, the last treatment was applied before entering the VCC. Subjective symptom scores, nasal airflow and nasal secretion were measured regularly during allergen challenge. Results: Budesolv 10 was equally effective compared to RA with respect to TNSS and nasal airflow after eight days of treatment with a strongly reduced dose (more than 80% reduction). After first dose, only Budesolv 10 showed a significant reduction of nasal and respiratory symptoms starting 90 minutes ( P < .05) and 15 minutes ( P < .05) after application onwards, respectively, demonstrating an early onset of efficacy. A clinically significant 1 point reduction in nasal symptom score was reached at 195 minutes ( P < .05) after application. Conclusions and clinical relevance: The novel preservative‐free, aqueous low‐dose budesonide formulation is highly efficacious even after an initial single treatment. Thus, Budesolv 10 appears to be an effective acute treatment for allergic rhinitis as well as for AR comorbidities like mild asthma and conjunctivitis.